• Dry Cracked Skin
  • General Dermatology
  • Impetigo
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

The Weekly Roundup: March 20-24

Article

ICYMI, this week we had stories about session highlights from AAD 2023, FDA approvals of biosimilars and MCC treatments, the association between the Mediterranean diet and tumor response rates, and more.

Advancements in Understanding the Skin's Microbiomes

Adam Friedman, MD, FAAD, offers highlights from his session at AAD 2023 on how cutaneous dysbiosis plays a role in some common skin conditions.

Establishing a Culture of Respect: Responding to Patient-Initiated Harassment

The impacts of discrimination, harassment, and microaggressions have lasting impact on a clinician’s performance, mental health, and career. Here’s how to create a respectful culture.

Raj Chovatiya, MD, PhD, Discusses All Things Inflammatory Diseases at AAD 2023

With the recent therapeutic revolution, there has never been a better time to find the right treatment option for your patient suffering from inflammatory diseases.

Study Finds Successful Switching Strategy for Patients with Psoriasis After Suboptimal Response

What can you do when a medication for psoriasis yields a suboptimal response? New data presented at the 2023 AAD Annual Meeting provides valuable insight on next steps for treatment.

Isotretinoin Best Practices: New Formulations, Avoiding Relapses, and More

Joshua Zeichner, MD, delivered a boot camp on isotretinoin use at AAD 2023, including an overview of newer formulations of the acne drug that could help counter the common absorption challenges.

Treating Body Dysmorphic Disorder in Cosmetic Patients

Patients with common psychocutaneous diseases, including body dysmorphic disorder (BDD), often refuse a psychiatric referral and instead, present to dermatologists and cosmetic surgeons.

Treating the Chest with Care on a Transgender Patient

A review on breast cancer screenings and procedures on the chest is essential to ensure proper gender-affirming care.

Expert Tips on Alopecia Management From AAD 2023

Ronda Farah, MD, FAAD, shares her tips and tricks for treating varying types of alopecia.

Berdamizer Gel Safe, Well-Tolerated in Patients With Molluscum Contagiosum

The treatment was deemed effective following a phase 3 study.

Tips to Organize the Digital Chaos with Alina Bridges, DO

In a world where she practices dermatology, conducts research, and is a super mom, Alina Bridges, DO has nailed down a strategy to not let emails stress her out.

Annual Meeting Session Highlights Clinical Pearls in Medical Dermatology

A key session at the annual meeting will share practical advice and tools to better support you and your patients.

Oral Ivarmacitinib Demonstrates Significant Atopic Dermatitis Improvement

Results from the phase 3 study were presented at an AAD late-breaking research session.

Skin Barrier 101: Keep Up with What Your Patients Are Reading

Jack Arbiser, MD, PhD discusses the connection between the skin barrier and anti-aging products.

Indoor Tanning and Melanoma

The use of tanning beds has become a popular practice in society today, however, it remains undisputed that ultraviolet radiation from natural sunlight and indoor tanning machines increases an individual’s risk of developing skin cancer.

FDA Approves Adalimumab-Adaz High-Concentration Formulation

Sandoz, a Novartis division, expects to launch the new adalimumab biosimilar on July 1, 2023.

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

By week 24 of the phase 3 study, a quarter of participants felt their vitiligo had improved.

Phase 3 Data for Bimekizumab Shows Well Maintained Response

A pair of phase 3 trials met all primary and secondary endpoints after 48 weeks.

New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients

A pediatric dermatologist and pediatric allergist translated guidelines into clinical practice at AAD 2023.

AAD 2023 Pearls from Zoe Diana Draelos, MD

Draelos shares her top takeaways from the annual AAD meeting in New Orleans.

Roflumilast Safe and Efficient for Patients with Chronic Plaque Psoriasis

Results from the phase 3 DERMIS-1 and DERMIS-2 trials were presented at the 2023 American Academy of Dermatology Annual Meeting.

New TMB-001 Sub-Analysis Data Published in Clinical and Experimental Dermatology

Timber Pharmaceuticals is on its way to developing the first FDA-approved treatment for congenital ichthyosis subtypes.

Risankizumab Efficacious in Patients with Prior Plaque Psoriasis Biologic Use

Prior use of biologics in patients with plaque psoriasis may not impact the efficacy of risankizumab treatment.

FDA Approves Retifanlimab-Dlwr for the Treatment of Metastatic or Recurrent Locally Advanced MCC

Incyte’s MCC indication is approved under accelerated approval based on tumor response rate and duration of response.

Oleogel-S10 for Epidermolysis Bullosa Wounds Demonstrated Accelerated Healing

Phase 3 data of Oleogel-S10 was presented in a late-breaking session at AAD 2023 in New Orleans.

Latinx, Hispanic Patients with Alopecia Carry Greater Disease Burden Than White Patients

Researchers sought to analyze alopecia areata data in populations historically underrepresented in research.

Oral Vitamin D Supplementation May Lower Melanoma Risk

Researchers were unable to determine a definite correlation.

Skin Cancer Detection Device Backed by Studies

DermaSensor’s handheld device is awaiting FDA review.

Lauren Miller, PA-C, Discusses SDPA and Updates in Dermatology

Miller shares upcoming news from the SDPA and important legislative updates for dermatology physician assistants.

Frontline Forum Part 3: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

In part 3 of this Frontline Forum series, Joshua Zeichner, MD, FAAD; Hilary Baldwin, MD; Zoe Diana Draelos, MD; Aaron S. Farberg, MD, FAAD; and Leon H. Kircik, MD, discuss the main pillars of acne and topical treatments available for patients with acne.

Pregnant Women with Skin Conditions May Require Dermatologic Intervention

Pregnant women with atopic dermatitis and psoriasis may require special treatment considerations.

Upadacitinib Advances to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

The selective and reversible Janus kinase inhibitor is being studied in several immune-mediated inflammatory diseases.

New Technology Could Allow Us to Rethink Alopecia Scores

Study investigators said this system could have significant clinical implications.

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

The study also found lasting benefits of the supplement for bone density up to age 4.

Highlights from AAD 2023

More than 300 innovative sessions, an engaging exhibit hall, and heartfelt networking—there was a lot to pack into AAD 2023! Here are the highlights.

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

Researchers say the impacts may be more harmful than those caused by industrial air pollutants.

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

Researchers say the treatment is both safe and effective in moderate-to-severe cases.

Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma

The UK and Netherlands study assessed tumor response rates among 91 patients.


Related Videos
© 2024 MJH Life Sciences

All rights reserved.